The abstract is read at the publisher; the summary is JClub's.
ACS recommends PSA-based prostate cancer screening that reduces mortality and advanced-stage diagnosis, with biennial screening for average-risk men ages 50–69 and annual screening for higher-risk groups.
- Why it matters: Screening aims to find clinically significant prostate cancer earlier, while minimizing harms from PSA testing, follow-up evaluations, and overdiagnosis.
- What they did: The ACS used a systematic review plus commissioned modeling to assess PSA screening strategies, then issued risk-stratified guidance by age and race/family history and PSA thresholds (≥3.0 ng/mL at 45–69; ≥6.5 ng/mL at 70–74).
- The result: Benefits were concluded to outweigh harms, and men with persistently elevated PSA should receive MRI and/or a validated biomarker to guide biopsy; screening is not recommended with life expectancy <10 years and should stop at age 75.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.